Creating new compounds to help develop drugs for Alzheimer's disease
Official title: Development of Efficient Carbon Carbon Bond Formations for Novel Se-, S-, and O-Heterocycle Synthesis
Funded at Winston-Salem State University · NIH-11034361 · Data updated 2026-11-12
This study is working on new ways to make special compounds that could help create better medicines for Alzheimer's disease, aiming to find new treatments that might improve patients' lives.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Winston-Salem State University NIH-funded |
| Lab location | 1 site (Winston-Salem, United States) |
| Project start | August 15, 2022 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $61,218 |
| NIH project number | 3R16GM145541-03S1 |
| Project ID | NIH-11034361 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research would be individuals affected by Alzheimer's disease or those at risk of developing it.
✕Less likely to help
Patients with conditions unrelated to Alzheimer's disease or those not interested in experimental drug therapies may not receive benefit from this research.
What this research studies
This research focuses on developing efficient methods to create complex organic compounds known as heterocycles, which are crucial for pharmaceutical applications, particularly in treating Alzheimer's disease. The approach involves using metal-catalyzed reactions to form carbon-carbon bonds, enabling the synthesis of novel compounds containing selenium, sulfur, and oxygen. By improving the efficiency and selectivity of these chemical processes, the research aims to generate bioactive heterocycles that could lead to new therapeutic options. Patients may benefit from the resulting drugs that target Alzheimer's disease and other conditions.
Why it matters
Potential benefit: If successful, this research could lead to the development of new medications that improve treatment options for Alzheimer's disease.
How similar studies have gone: Other research has shown success in developing new drug compounds through similar synthetic approaches, indicating potential for impactful advancements.
Where this research is happening
-
Winston-Salem State University
Winston-Salem, United States Active
Researchers
- Principal investigator: Guo, Fenghai — Winston-Salem State University
- Study coordinator: Guo, Fenghai
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.